Tenet Healthcare director sells 3,952 shares at $176.39 — Form 4

Tenet Healthcare insider sale: Director Christopher S. Lynch sold 3,952 shares of Tenet Healthcare Corporation common stock on 08/19/2025 at a reported price of $176.39 per share, leaving him with 12,358 shares beneficially owned after the sale.

Rhea-AI Filing Summary

Tenet Healthcare insider sale: Director Christopher S. Lynch sold 3,952 shares of Tenet Healthcare Corporation common stock on 08/19/2025 at a reported price of $176.39 per share, leaving him with 12,358 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/21/2025. The filing identifies Lynch as a director and the transaction is a direct sale of common stock.

Insights

Financial Analyst

TL;DR: A routine director sale of 3,952 shares at $176.39; no other transactions or derivatives disclosed.

This Form 4 documents a single, direct sale by a Tenet Healthcare director that reduced his holdings to 12,358 shares. The trade date and price are explicitly reported, and no option exercises or derivative transactions accompany the sale. As a standalone disclosure, the transaction represents routine insider liquidity rather than a clearly material corporate development.

Corporate Governance Expert

TL;DR: Insider sale disclosed properly; filing signed by attorney-in-fact, indicating procedural compliance.

The filing shows required Section 16 reporting: the reporting person is identified as a director and the Form 4 was executed by an attorney-in-fact. There are no indications of Rule 10b5-1 plan notation or multiple reporting persons. The disclosure meets the form's requirements but contains no governance events or policy changes.

Insider Trade Summary

Net Seller: 3,952 shares

Net Sell 1 txn

Insider Lynch Christopher S.

Role Director

Sold 3,952 shs ($697K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,952	$176.39	$697K

Holdings After Transaction: Common Stock — 12,358 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tenet Healthcare (THC) insider Christopher S. Lynch report on Form 4?

He reported a direct sale of 3,952 shares of Tenet Healthcare common stock on 08/19/2025 at a price of $176.39 per share, leaving him with 12,358 shares.

When was the Form 4 for Christopher S. Lynch executed and who signed it?

The Form 4 lists an execution signature by Chad J. Wiener, as Attorney-in-fact for Christopher S. Lynch dated 08/21/2025.

Does the filing show any derivative transactions or option exercises for Lynch?

No. The filing contains only a non-derivative transaction: a sale of common stock. No derivatives or options are reported.

How is Christopher S. Lynch identified in the Form 4 filing for THC?

He is identified as a Director of Tenet Healthcare Corporation and the form indicates it was filed by one reporting person.

Is there any indication the transaction was made under a 10b5-1 trading plan?

The Form 4 does not indicate that the sale was made pursuant to a Rule 10b5-1 plan; no such box or notation appears in the disclosed content.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/21/2025 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lynch Christopher S.

(Last) (First) (Middle)

14201 DALLAS PARKWAY

(Street)

DALLAS TX 75254

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TENET HEALTHCARE CORP [ THC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		S		3,952	D	$176.39	12,358	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Chad J. Wiener, as Attorney-in-fact for Christopher S. Lynch	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.